ANI Pharmaceuticals, Inc. Stock Prediction
AI-powered sentiment analysis and prediction trends for ANIP, updated each market day.
ANIP AI Sentiment
AI sees no strong directional signal for ANI Pharmaceuticals, Inc. stock over the next 10 market days.
Prediction date: April 30, 2026
Subscribers see precise scores, buy/sell targets, and full analytics.
About ANI Pharmaceuticals, Inc.
ANI Pharmaceuticals Inc is a diversified biopharmaceutical company. It is focused on developing, manufacturing, and commercializing therapeutics through its Rare Disease business, which markets novel products in the areas of ophthalmology, rheumatology, nephrology, neurology, and pulmonology; and through its Generics and Brands businesses. The firm's product portfolio comprises Purified Cortrophin Gel, ILUVIEN, and YUTIQ (fluocinolone acetonide intravitreal implant), among others. Additionally, its Generics portfolio includes several products with a wide variety of indications. The company has two operating segments: Rare Disease and Brands, which derive maximum revenue, and Generics and Other. Geographically, it generates maximum revenue from the United States, followed by other markets.
Sector
Exchange
Market Cap
$1,775,880,455
Cap Tier
Employees
970
Headquarters
BAUDETTE, MN
Listed Since
Sept. 13, 1999
ANIP Sentiment Trend — Last 30 Predictions
Sentiment zones: Bullish · Neutral · Bearish
ANIP Volatility
ANI Pharmaceuticals, Inc. has shown moderate price volatility over the last 5 trading days. Moderate volatility indicates normal market activity with typical price fluctuations.
